Menu
Close
.svg)
During our annual company meeting in Philadelphia last week, our AI team demonstrated something that honestly stopped me in my tracks. It was next-generation technology where the application was immediately obvious: a major step forward in how we conduct qualitative marketing research.
It wasn’t another clever algorithm or generative AI tool promising incremental efficiency gains. It was something much more tangible for those of us who have spent decades designing and implementing research in the pharmaceutical industry.
It was a fully lifelike AI avatar delivering a product detail.
For anyone who remembers how visual aid testing used to be conducted and has seen the various ways in which detail aid testing has evolved, the implications are enormous. And I’m genuinely excited to start working with our clients this year to put this technology to work.
When I first started running visual aid testing studies back in the early 1990's, the gold standard stimulus was simple: bring in an actual sales representative.
You would pull a sales representative from the field for the duration of the research and ask them to perform a mock detail in front of physician respondents. The rep would walk through the visual aid exactly as they would during a real 1:1 sales call. It was pretty authentic, dynamic, and incredibly valuable. Once the detail was complete during each interview, the moderator would step in to probe deeply: how well the visual aid performed, which messages resonated, and where the document could be strengthened.
There were several advantages to this approach.
First, the realism was unmatched. Physicians interacted naturally with the live rep, asking questions the same way they would during a real office visit. This allowed the research team to identify common objections and frequently asked questions in real time.
Second, the format was flexible. If something in the script wasn’t resonating, you could modify the language between interviews. Within a handful of physician discussions, you could refine the messaging considerably.
Of course, there was also a downside: you had just taken a productive sales representative out of the field for several days.
To solve that problem, many research teams turned to what became known as the “rep-in-a-box.”
This was essentially an audio recording of a sales representative performing the product detail. The moderator would play the recording while showing the visual aid to physicians during the interview. I'm old enough to remember when we used a cassette tape.
It was efficient and consistent. No travel logistics. No pulling someone from the field. Just hit play.
But something was missing.
Without a human presence, the interaction became more artificial. Physicians were listening to a voice rather than engaging with a person. The nuance of body language, eye contact, and conversational pacing disappeared.
The rep-in-a-box solved operational problems, but it sacrificed realism.
For years, the industry accepted that tradeoff. And it has largely shaped how visual aid testing has been conducted over the past decade, as qualitative research shifted from in-facility interviews to virtual sessions on research platforms like Civicom or Forsta.
Fast forward to 2026, and we’re now entering an entirely new chapter.
Over the past year, our AI team has been experimenting with next-generation avatar technology. During last week’s demonstration, they showed a platform capable of creating a lifelike digital presenter from a short video recording of a real person’s face and upper torso.
The result is remarkable.
The avatar delivers a scripted product detail while displaying natural facial expressions, realistic pacing, and conversational cadence. The presentation looks and sounds like a real sales representative speaking directly to the physician.
If you weren’t told it was AI-generated, you might not know.
For those of us who remember the early days of avatars -- when they looked like characters borrowed from a Roblox game -- the progress is astonishing. The fidelity is dramatically higher, and the cost is dramatically lower.
This is not experimental technology anymore. It’s ready for real research applications.
The implications for master visual aid testing are profound.
First, the avatar ensures an extraordinarily consistent stimulus. Every physician hears the same message, delivered with the same pacing and emphasis. From a research design standpoint, that level of uniformity is incredibly valuable.
Second, the script can be modified instantly. If the research team wants to test an alternate message between interviews, the change can be implemented immediately.
Third -- and this is particularly important in pharmaceutical research -- the delivery is fully compliant. Because the avatar follows a programmed script, there is no risk that the presentation drifts into off-label territory or introduces unintended claims.
Anyone who has conducted pharmaceutical research knows how important that safeguard can be.
Another advantage is scale.
The platform our team has been evaluating supports up to 30 languages, including the most widely spoken languages across global pharmaceutical reference markets.
That means the same visual aid presentation can be delivered in English, Spanish, Mandarin, German, Japanese, or Portuguese with remarkable fidelity. The messaging remains consistent while the language adapts to the local audience.
For global marketing research studies, that is a major step forward.
Instead of producing multiple localized recordings or coordinating different presenters across regions, researchers can deploy one standardized stimulus worldwide.
In many ways, this approach combines the strengths of the two legacy methods. It's the best of both worlds.
Like the live representative, the avatar creates a highly realistic presentation that feels natural to physicians. They see a face, observe expressions, and follow a narrative delivered by what appears to be a human presenter.
At the same time, the operational simplicity resembles the rep-in-a-box model. There’s no need to coordinate field personnel, schedule rehearsals, or manage travel.
You simply deploy the avatar.
The result is a stimulus that is both scalable and lifelike -- something the industry has never quite had before.
For those of us who have watched this industry evolve over the years, who have lived analog to digital, moments like this are exciting because they reveal where AI can deliver real, practical value.
Visual aid testing -- one of the most important and fundamental tools in pharmaceutical marketing research -- is being reinvented in real time.
We are suddenly able to create stimuli that are consistent, compliant, multilingual, and remarkably human.
And if you take the concept one step further, it raises an intriguing question.
If an AI avatar can convincingly simulate a sales representative in research, it’s not hard to imagine a future where digital twins of sales reps are used in actual physician education or remote detailing.
What we saw last week may not just change visual aid testing.
It may be an early glimpse into the future of pharmaceutical engagement itself.
One thing is certain: the toolkit for primary marketing research just got a lot more powerful.
